# Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

Source: https://onco.cc/trials/nct06312670/  
OnCo record `nct06312670` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Masofaniten and Enzalutamide in Metastatic hormone-sensitive prostate cancer and Prostate cancer, run by Pedro Barata, MD, MSc, completed.

## Summary

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer is a phase 2 interventional study registered as NCT06312670 by Pedro Barata, MD, MSc, with 13 participants recorded, started 2024-05-16 and reaching its primary completion in 2025-01-09. Interventions recorded: EPI-7386, Enzalutamide, Androgen Deprivation Therapy (ADT). Conditions recorded: Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma.

Linked to the drug Masofaniten because the registry names it among its interventions and Metastatic hormone-sensitive prostate cancer and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06312670
- Phase: 2
- Setting: Phase 2 Trial Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
- Sponsor: Pedro Barata, MD, MSc
- Enrolled: 13

## Sources

- ClinicalTrials.gov NCT06312670: https://clinicaltrials.gov/study/NCT06312670

## Connected records

- cancers: [Metastatic hormone-sensitive prostate cancer](https://onco.cc/cancers/prostate-mhspc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [Masofaniten](https://onco.cc/drugs/masofaniten/)

---
JSON: https://onco.cc/api/v1/entities/nct06312670.json